Shares fell 9.5% following the quarter as investors reacted negatively to cautious early sales performance and a lack of clear near-term revenue acceleration despite a successful product launch and broad coverage progress.

• CARDAMYST launched quickly after FDA approval in December 2025 and became available nationwide by end of January 2026.
• Approximately 600 total prescriptions were recorded through April, with steady month-over-month growth but still limited penetration.
• Over 400 unique prescribers and about 560 unique patients indicated initial broad physician interest, yet script volume remains modest.
• Early coverage includes 25% of commercially insured patients, anchored by Express Scripts formulary inclusion.
• Management highlights positive patient and provider feedback but does not provide explicit revenue or profit guidance, suggesting cautious outlook.